Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GSK Paxil Hemihydrate Patent Claim Invalid, Court Says In Ruling For Apotex

This article was originally published in The Pink Sheet Daily

Executive Summary

SmithKline’s early clinical trials on the safety and efficacy of paroxetine hemihydrate as an antidepressant did not constitute an “experimental use” of the claimed invention, the court says.

You may also be interested in...

Paxil Patent Ruling Revised: Will GSK’s Loss Be A Gain For Lilly’s Zyprexa?

Paroxetine patent was “inherently anticipated” by an earlier patent, court says. Appellate panel changes its reasoning from an earlier opinion, in which it said the patent was invalidated by the “public use” bar. Revised language means Zyprexa patent challengers cannot cite the case in arguing olanzapine clinical trials constituted prior public use.

US FDA Facility Compliance Actions Could Speed Up Despite Inspections Freeze, Attorney Says

With inspectors no longer out in the field, they have more time to wrap up work on previously completed facility evaluations, attorney Howard Sklamberg says; inspections freeze could delay manufacturers’ abilities to bring facilities into compliance following adverse inspection findings, as well as agency reclassifications of facility status.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts